Article

A transient amphipathic helix in PCSK9’s prodomain facilitates low-density lipoprotein binding

2019-08-22

Abstract excerpt

<h4>SUMMARY</h4> Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a ligand of low-density lipoprotein receptor (LDLR) that promotes LDLR degradation in late endosomes/lysosomes. In human plasma, 30-40% of PCSK9 is bound to LDL particles; however, the physiological significance of this interaction remains unknown. LDL binding in vitro requires a disordered N-terminal region in PCSK9’s prodomain. Here we r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51525f6e-16fc-51c4-a8c5-c21e69d46f14
DOI: 10.1101/743195

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A transient amphipathic helix in PCSK9’s prodomain facilitates low-density lipoprotein bindingDOI 10.1101/743195Read

A transient amphipathic helix in the prodomain of PCSK9 facilitates binding to low-density lipoprotein particles.Semantic proximity Read

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants.Semantic proximity Read

Structural Dynamics of LDL Receptor Interactions with E498A and R499G Variants of PCSK9Semantic proximity Read

Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.Semantic proximity Read

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.Semantic proximity Read

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read

[PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].Semantic proximity Read

Potent Efficacy of Computer-Aided Designed Peptide Degrader Drug on PCSK9-Mediated HypercholesterolemiaSemantic proximity Read

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Semantic proximity Read

Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed MutagenesisSemantic proximity Read

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Semantic proximity Read